Adagene Raises $25 Million to Accelerate AI-Driven Breakthroughs in Cancer Immunotherapy

Adagene Inc. (Nasdaq: ADAG), a transformative force in the biotechnology landscape, is proud to announce a successful funding round that raised $25,000,000. This significant infusion of capital will accelerate the company’s mission of revolutionizing the discovery and development of novel antibody-based cancer immunotherapies. By leveraging its proprietary DPL platform—which includes the cutting-edge technologies NEObody, SAFEbody™, and POWERbody™—Adagene is uniquely positioned to harness the power of computational biology and artificial intelligence in designing innovative antibodies aimed at addressing critical unmet patient needs. The funding will bolster the company’s highly differentiated pipeline, enabling the advancement of novel immunotherapy programs and opening new avenues for precision medicine in the fight against cancer. Moreover, this investment reflects strong confidence from investors in Adagene’s scientific approach and strategic vision. The fresh capital is earmarked for expanding research and development capabilities, furthering technological innovation, and strengthening strategic collaborations with reputable global partners. These partnerships are key in leveraging Adagene’s expertise across multiple approaches at the cutting edge of cancer treatment, thus fostering a dynamic ecosystem that bridges computational insights with clinical applications. As the company continues to push the boundaries of science in oncology, the new funds will also support the scaling of operations and the enhancement of its digital platforms, ensuring that groundbreaking discoveries reach the forefront of cancer care. With this milestone achievement, Adagene is set to redefine the landscape of cancer immunotherapy and provide renewed hope for patients worldwide.